Evidence map›Paper›PMID 40454094›Full record

ArticleiScience2025

Drug repurposing reveals posaconazole as a CYP11A1 inhibitor enhancing anti-tumor immunity.

Jhuma Pramanik, Sanu Korumadathil Shaji, Megan Zaman, Bethany Brown, Baojie Zhang, Yumi Yamashita-Kanemaru, Natalie Z M Homer, Hosni A M Hussein, Qiuchen Zhao, Klaus Okkenhaug and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jhuma PramanikDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Sanu Korumadathil ShajiDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Megan ZamanDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Bethany BrownDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Baojie ZhangDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Yumi Yamashita-KanemaruDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Natalie Z M HomerMass Spectrometry Core, Edinburgh Clinical Research Facility, Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Hosni A M HusseinDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Qiuchen ZhaoDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Klaus OkkenhaugDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Rahul RoychoudhuriDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Abhik MukhopadhyayCambridge Crystallographic Data Centre, Cambridge CB2 1EZ, UK.
Bidesh MahataDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Steroid hormones regulate cell physiology and immune function, with dysregulated steroidogenesis promoting cancer progression by supporting tumor growth and suppressing anti-tumor immunity. Targeting CYP11A1, the first and rate-limiting enzyme in steroid biosynthesis, has shown promise in cancer therapy, but safe and effective inhibitors remain an unmet need. Undertaking

Indexed as

Biological sciencesCancer systems biologyNatural sciencesPharmacologySystems biology

Identifiers

PMID40454094
PMCPMC12124671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.